Effect of BI 764198 on Metformin Pharmacokinetics in Healthy Participants

Phase 1, randomised, open-label trial of apecotrep (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ up to 5 days and Maximum measured concentration of the analyte in plasma at steady state up to 5 days. Started Feb 2026; status: completed.